[go: up one dir, main page]

WO2010057152A3 - Molécules d'arn chimériques inter-espèces - Google Patents

Molécules d'arn chimériques inter-espèces Download PDF

Info

Publication number
WO2010057152A3
WO2010057152A3 PCT/US2009/064707 US2009064707W WO2010057152A3 WO 2010057152 A3 WO2010057152 A3 WO 2010057152A3 US 2009064707 W US2009064707 W US 2009064707W WO 2010057152 A3 WO2010057152 A3 WO 2010057152A3
Authority
WO
WIPO (PCT)
Prior art keywords
pathogen
host cell
cross
rna molecules
chimeric rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/064707
Other languages
English (en)
Other versions
WO2010057152A2 (fr
WO2010057152A8 (fr
Inventor
Jen-Tsan Chi
Gregory Lamonte
Nisha Philip
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of WO2010057152A2 publication Critical patent/WO2010057152A2/fr
Publication of WO2010057152A3 publication Critical patent/WO2010057152A3/fr
Publication of WO2010057152A8 publication Critical patent/WO2010057152A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/01—Methyltransferases (2.1.1)
    • C12Y201/01017—Phosphatidylethanolamine N-methyltransferase (2.1.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des procédés pour réduire l’expression d’au moins un gène d’un pathogène intracellulaire dans une cellule hôte, où le procédé comprend l’introduction dans une cellule hôte d’un polynucléotide hétérologue comprenant ou codant pour un miARN qui fusionne avec au moins un ARNm du pathogène et réduit la traduction de l’ARNm. La présente invention concerne en outre des compositions pharmaceutiques comprenant de tels polynucléotides, où la réduction de l’expression du gène pathogène conduit à une inhibition de croissance ou de différenciation du pathogène ou une réduction de l’infection d’une cellule hôte avec le pathogène, ainsi que des procédés de traitement de maladies causées par un pathogène chez des sujets par administration des compositions pharmaceutiques.
PCT/US2009/064707 2008-11-17 2009-11-17 Molécules d'arn chimériques inter-espèces Ceased WO2010057152A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11536808P 2008-11-17 2008-11-17
US61/115,368 2008-11-17

Publications (3)

Publication Number Publication Date
WO2010057152A2 WO2010057152A2 (fr) 2010-05-20
WO2010057152A3 true WO2010057152A3 (fr) 2010-08-26
WO2010057152A8 WO2010057152A8 (fr) 2010-09-23

Family

ID=42170793

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/064707 Ceased WO2010057152A2 (fr) 2008-11-17 2009-11-17 Molécules d'arn chimériques inter-espèces

Country Status (1)

Country Link
WO (1) WO2010057152A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076622A2 (fr) * 2003-02-10 2004-09-10 National Institute Of Advanced Industrial Science And Technology Regulation de cellules mammaliennes
US20050075492A1 (en) * 2003-08-07 2005-04-07 Whitehead Institute For Biomedical Research Methods and products for expression of micro RNAs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076622A2 (fr) * 2003-02-10 2004-09-10 National Institute Of Advanced Industrial Science And Technology Regulation de cellules mammaliennes
US20050075492A1 (en) * 2003-08-07 2005-04-07 Whitehead Institute For Biomedical Research Methods and products for expression of micro RNAs

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RATHJEN, T.: "Analysis of short RNAs in the malaria parasite and its red blood cell host.", FEBS LETTERS, vol. 580, no. 22, 2006, pages 5185 - 5188 *
WINTER, F. ET AL.: "Anopheles gambiae miRNAs as actors of defence reaction against Plasmodium invasion.", NUCLEIC ACIDS RESEARCH, vol. 35, no. 20, 12 October 2007 (2007-10-12), pages 6953 - 6962 *

Also Published As

Publication number Publication date
WO2010057152A2 (fr) 2010-05-20
WO2010057152A8 (fr) 2010-09-23

Similar Documents

Publication Publication Date Title
EP3418386A3 (fr) Compositions et méthodes permettant d'inhiber l'expression d'un gène du virus de l'hépatite b
MX2015011943A (es) Acidos ribonucleicos con nucleotidos modificados por 4'-tio y metodos relacionados.
WO2011038160A3 (fr) Compositions et procédés pour réduire au silence des gènes exprimés dans le cancer
WO2011072082A3 (fr) Modulation de l'expression de hsp47
WO2009045370A3 (fr) Constructions et bioréacteurs de commutation de gène théapeutique destinés à l'expression de molécules biothérapeutiques, et utilisation de ceux-ci
WO2012024396A3 (fr) Compositions et méthodes permettant d'administrer des molécules d'acide nucléique et de traiter un cancer
WO2010017436A3 (fr) Modulation de l’expression du gène de réponse primaire de différenciation de cellules myéloïdes 88 (myd88) par des oligonucléotides antisens
WO2012075040A3 (fr) Arnm pour l'utilisation dans le traitement de maladies génétiques humaines
MX2021000211A (es) Metodos y productos para transfeccion de celulas.
WO2008131191A3 (fr) Acides nucléiques hybridables avec des précurseurs des micro-arn de ceux-ci
WO2009036933A3 (fr) Régulation à la baisse de l'expression génique à l'aide de particules pseudovirales chargées d'acide nucléique
WO2012135246A3 (fr) Compositions et méthodes permettant d'inhiber l'expression du gène tmprss6
WO2010017152A3 (fr) Modulation de l'expression de récepteur de type toll 8 par des oligonucléotides antisens
WO2012046085A3 (fr) Procédés de déclenchement de la production d'insuline
WO2010003420A3 (fr) Traitement du psoriasis et de maladies apparentées par modulation de miarn
WO2010017154A3 (fr) Modulation de l'expression de récepteur de type toll 3 par des oligonucléotides antisens
WO2007137156A3 (fr) Modulation d'aha par l'arn et utilisateurs thérapeutiques de celle-ci
WO2010025321A3 (fr) Procédé de traitement de patients souffrant de sclérose en plaques avec des anticorps anti-il2r
WO2009086428A3 (fr) Procédés et compositions destinés à augmenter l'expression génique
WO2012177008A3 (fr) Composition pour réguler la chromogenèse comprenant un microarn
WO2009111336A3 (fr) Procédés pour purifier de l'adn plasmidique
BR112013014082A2 (pt) "moléculas de rna, micro-rna e de ácido nucleico, composições e construtos compreendendo as mesmas, bem como métodos para melhorar a resistência 5 de uma planta à infecção, controlar a infecção e reduzir o desenvolvimento do cisto de um nematódeo, para produção de uma célula ou de uma planta possuindo resistência a nematódeo e para melhorar a produtividade".
WO2010109176A3 (fr) Composition destinée à être utilisée en thérapie génique
WO2011054939A3 (fr) Compositions et procédés pour inhiber l'expression de gènes kif10
WO2010017131A3 (fr) Modulation de l'expression de récepteur de type toll 7 par des oligonucléotides antisens

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09826947

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09826947

Country of ref document: EP

Kind code of ref document: A2